Interleukin 2 in cancer therapy

Current Medicinal Chemistry

Volumn 17, Issue 29, 2010, Pages 3297-3302

  Antony, G K ^a   Dudek, A Z ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

Immunotherapy; Interleukin 2; Kidney cancer; Melanoma

Indexed keywords

CANCER VACCINE; IMMUNOMODULATING AGENT; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 2 RECEPTOR BETA; RECOMBINANT INTERLEUKIN 2;

ADULT RESPIRATORY DISTRESS SYNDROME; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CHILL; CLINICAL ASSESSMENT; CONFUSION; CONTINUOUS INFUSION; DIARRHEA; DRUG ACTIVITY; DRUG DOSE REGIMEN; EDEMA; EOSINOPHILIA; ERYTHRODERMA; FEVER; GENE EXPRESSION; HEART INFARCTION; HUMAN; HYPOTENSION; IN VITRO STUDY; INTENSIVE CARE UNIT; KIDNEY CANCER; KIDNEY CARCINOMA; LETHARGY; MELANOMA; METASTASIS; MYOCARDITIS; NAUSEA; SIDE EFFECT; SIGNAL TRANSDUCTION; THROMBOCYTOPENIA; UREMIA;

EID: 77957936264     PISSN: 09298673     EISSN: None     Source Type: Journal    
DOI: 10.2174/092986710793176410     Document Type: Article

References (63)

1. Bain, B.; Vas, M.R.; Lowenstein, L. The development of large immature mononuclear cells in mixed leukocyte cultures. Blood, 1964, 23, 108.
2. Bach, F.; Hirschhorn, K. Lymphocyte Interaction: A potential histocompatibility test in vitro. Science, 1964, 143, 813.
3. Gordon, J.; Maclean, L.D. A lymphocyte-stimulating factor produced in vitro. Nature, 1965, 208, 795-798.
4. Morgan, D.; Ruscetti, F.W.; Gallo, R. Selective in-vitro growth of T-lymphocytes from normal bone marrows. Science, 1976, 193, 1007.
5. Mier, J.; Gallo R. Purification and some characteristics of human T cell growth factor (TCGF). Proc. Natl. Acad. Sci. U.S.A., 1980, 77, 6134-6138.
6. Wang, A.; Lu, S.D.; Mark, D.F. Site-specific mutagenesis of the human interleukin-2 gene: structure-function analysis of the cysteine residues. Science, 1984, 224, 1431-1433.
7. Wang, X.; Rickert, M.; Garcia, K.C. Structure of the quaternary complex of Interleukin-2 with its alpha, beta and gamma receptors. Science, 2005, 310, 1159-1163.
8. Taniguchi, T.; Minami, Y. The IL-2/IL-2 receptor system: A current overview. Cell, 1993, 73, 5.
9. Takeshita, T.; Asao, H.; Ohtani, K.; Ishii, N.; Kumaki, S.; Tanaka, N.; Munakata, H.; Nakamura, M.; Sugamura, K. Cloning of the gamma-chain of the human IL-2 receptor. Science, 1992, 257, 379-382.
10. Torigoe, T.; O'Connor, R.; Fagard, R.; Fischer, S.; Santoli, D.; Reed, J.C. Regulation of SRC-family protein tyrosine kinases by interleukins, IL-2, and IL-3. Leukemia, 1992, 6, 94S-97S.
11. Hatakeyama, M.; Kono, T.; Kobayashi, N.; Kawahara, A.; Levin, S.D.; Perlmutter, R.M.; Taniguchi, T. Interaction of the IL-2 receptor with the src-family kinase p56lck:identification of novel intermolecular association. Science, 1991, 252, 1523-1528.
12. Russel, S.M.; Johnston, J.A.; Noguchi, M.; Kawamura, M.; Bacon, C.M.; Friedmann, M.; Berg, M.; McVicar, D.W.; Witthuhn, B.A.; Silvennoinen, O. Interaction of IL-2 beta and gamma c chains with JAK1 and JAK3;implications for XSCID and XCID. Science, 1994, 266, 1042-1045.
13. Wang, K.S.; Ritz, J.; Frank, D.A. IL-2 induces STAT4 activation in primary NK cells and NK cell lines, but not in T cells. J. Immunol., 1999, 162, 299.
14. Waldaman, T.A. The biology of IL-2 and IL-15.Implications for cancer therapy and vaccine design. Nat. Rev., 2006, 6, 595-601.
15. Numerof, R.P.; Aronson, F.R.; Mier, J.W. IL-2 stimulates the production of IL-1 alpha and IL-1 beta by human peripheral blood mononuclear cells. J. Immunol., 1988, 141, 4250-4257.
16. Nedwin, G.E.; Svedersky, L.P.; Bringman, T.S.; Palladino, M.A., Jr.; Goeddel, D.V. Effect of Interleukin 2, Interferon-gamma and mitogens on the production of tumor necrosis factors alpha and beta. J. Immunol., 1985, 135, 2492-2497.
17. Zhang, J.; Scordi, I.; Smyth, M.J.; Lichtenheld, M.G. Interleukin 2 receptor signaling regulates the perforin gene through signal transducer and activator of transcription (Stat)5 activation of two enhancers. J. Exp. Med., 1999, 190, 1297-1308.
18. Lotze, M.T.; Grimm, E.A.; Mazumder, A.; Strausser, J.L.; Rosenberg, S.A. Lysis of fresh and cultured autologous tumor by human lymphocytes cultured in T-cell growth factor. Cancer Res., 1981, 41, 4420-4425.
19. Strausser, J.L.; Mazumder, A.; Grimm, E.A.; Lotze, M.T.; Rosenberg, S.A. Lysis of human solid tumors by autologous cells sensitized in vitro to alloantigens. J. Immunol., 1981, 127, 266-271.
20. Rosenberg, S.A.; Mule, J.J.; Spiess, P.J.; Reichert, C.M.; Schwarz, S.L. Regression of pulmonary metastasis and subcutaneous tumors mediated by the administration of high dose recombinant IL-2. J. Exp. Med., 1985, 161, 1169-1188.
21. Thompson, J.A.; Peace, D.J.; Klarnet, J.P.; Kern, D.E.; Greenberg, P.D.; Cheever, M.A. Eradication of disseminated murine leukemia by treatment with high dose IL-2. J. Immunol., 1986, 137, 3675-3680.
22. Connor, J.; Bannerji, R.; Saito, S.; Heston, W.; Fair, W.; Gilboa, E. Regression of bladder tumors in mice treated with Interleukin-2 gene-modified tumor cells. J. Exp. Med., 1993, 177, 1127-1134.
23. Lotze, M.T.; Frana, L.W.; Sharrow, S.O.; Robb, R.J.; Rosenberg, S.A. In vivo administration of purified human interleukin 2. I. Halflife and immunologic effects of the Jurkat cell line-derived interleukin 2. J. Immunol., 1985, 134, 157-166.
24. Lafreniere, R.; Rosenberg, S.A. Adaptive Immunotherapy of murine hepatic metastases with lymphokine activated killer (LAK) cells and Recombinant Interleukin 2 (RIL2) can mediate the regression of both immunogenic and non-immunogenic sarcomas and an adenocarcinoma. J. Immunol., 1985, 135, 4273-4280.
25. Rosenberg, S.A.; Yang, J.C.; Topalian, S.L.; Schwartzentruber, D.J.; Weber, J.S.; Parkinson, D.R.; Seipp, C.A.; Einhorn, J.H.; White, D.E. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high dose bolus IL-2. JAMA, 1994, 271, 907-913.
26. Rosenberg, S.A.; Lotze, M.T.; Yang, J.C.; Aebersold, P.M.; Linehan, W.M.; Seipp, C.A.; White, D.E. Experience with the use of high dose IL-2 in the treatment of 652 cancer patients. Ann. Surg., 1989, 210, 474-485.
27. Rosenberg, S.A.; Lotze, M.T.; Muul, L.M.; Chang, A.E.; Avis, F.P.; Leitman, S.; Linehan, W.M.; Robertson, C.N.; Lee, R.E.; Rubin, J.T. A progressive report on the treatment of 157 patients with advanced cancer using lymphokine activated killer cells and IL-2 or high dose IL-2 alone. N. Engl. J. Med., 1987, 316, 889-897.
28. McCabe, M.S.; Stablein, D.; Hawkins, M.J. The modified Group C experience - Phase III randomized trials of IL-2 vs. IL-2+LAK in advanced renal cell carcinoma and advanced melanoma. Proc. Am. Soc. Clin. Oncol., 1991, 10, A714.
29. Bui, M.H.T.; Seligson, D.; Han, K.; Pantuck, J.; Dorey, F.J.; Huang, Y.; Horvath, S.; Leibovich, B.C.; Chopra, S.; Liao, S.; Stanbridge, E.; Lerman, M.I.; Palotie, A.; Figlin, R.A.; Belldegrun, A.S. Carbonic Anhydrase IX is an independent predictor of survival in Advanced renal cell Carcinoma: Implications for prognosis and therapy. Clin. Can. Res., 2003, 9, 802-811.
30. Atkins, M., Regan, M.; McDermott, D.; Mier, J.; Stanbridge, E.; Youmans, A.; Febbo, P.; Upton, M.; Lechpammer, M.; Signoretti, S. Carbonic Anhydrase IX expression predicts outcome of Interleukin 2 therapy for renal cancer. Clin. Can. Res., 2005, 11, 3714.
31. Dudek, A.Z.; Yee, R.T.; Manivel, J.C.; Isaksson, R.; Yee, H.O. Carbonic anhydrase IX expression is associated with improved outcome of high-dose interleukin-2 therapy for metastatic renal cell carcinoma. Anticancer Res., 2010, 30, 987-992.
32. Lotze, M.T.; Matory, Y.L.; Rayner, A.A.; Ettinghausen, S.E.; Vetto, J.T.; Seipp, C.A.; Rosenberg, S.A. Clinical effects and toxicities of IL-2 in patients with cancer. Cancer, 1986, 58, 2764-2772.
33. Rosenstein, M.; Ettinghausen, S.E.; Rosenberg, S.A. Extravasation of intravascular fluid mediated by systemic administration of recombinant Interleukin-2. J. Immunol., 1986, 137, 1735-1742.
34. Schuchter, L.M.; Hendricks, C.B.; Holland, K.H.; Shelton, B.K.; Hutchins, G.M.; Baughman, K.L.; Ettinger, D.S. Eosinophilic myocarditis associated with high dose Interleukin-2 therapy. Am. J. Med., 1990, 88, 439-440.
35. Klempner, M.; Noring, R.; Mier, J.; Atkins, M.B. An acquired neutrophil chemotactic defect in patients receiving immunotherapy with IL-2. N. Engl. J. Med., 1990, 322, 959-965.
36. Schwartenzuber, D.J. Guidelines for the safe administration of IL-2. J. Immunother., 2001, 24, 287-293.
37. Kammula, U.S.; White, D.E.; Rosenberg, S.A. Trends in the safety of high dose bolus IL-2 administration in patients with metastatic cancer. Cancer, 1998, 83, 797-805.
38. Guirguis, L.M.; Yang, J.C.; White, D.E.; Steinberg, S.M.; Liewehr, D.J.; Rosenberg, S.A.; Schwartzentruber, D.J. Safety and efficacy of high dose Interleukin 2 therapy in patients with brain metastasis. J. Immunother., 2002, 25, 82-87.
39. Powell, S.; Dudek, A.Z. Single-institution outcome of high-dose interleukin-2 (HD IL-2) therapy for metastatic melanoma and analysis of favorable response in brain metastases. Anticancer Res., 2009, 29, 4189-4193.
40. Yang, J.C.; Rosenberg, S.A. An ongoing prospective randomized comparison of IL-2 regimens for the treatment of metastatic renal cell cancers. Cancer J. Sci. Am., 1997, 3(Suppl 1), S79-84.
41. Petrella, T.; Quirt, I.; Verma, S.; Haynes, A.E.; Charette, M.; Bak, K. and members of the Melanoma Disease Site Group of Cancer Care Ontario's program in Evidence Based Care. Single agent IL-2 in the treatment of metastatic melanoma. Curr. Oncol., 2007, 14, 21-26.
42. Yang, J.C.; Sherry, R.M.; Steinberg, S.M.; Topalian, S.L.; Schwartzentruber, D.J.; Hwu, P.; Seipp, C.A.; Rogers-Freezer, L.; Morton, K.E.; White, D.E.; Liewehr, D.J.; Merino, M.J.; Rosenberg, S.A. Randomized study of high dose and low dose Interleukin-2 in patients with metastatic renal cancer. J. Clin. Oncol., 2003, 16, 3127-3132.
43. Devita, V.T.; Lawerence, T.S.; Rosenberg, S.A. Cancer. Principles and Practice of Oncology. 8th ed., 2008, pp. 508-514.
44. Atkins, M.B.; Sparano, J.; Fisher, R.I.; Weiss, G.R.; Margolin, K.A.; Fink, K.I.; Rubinstein, L.; Louie, A.; Mier, J.W.; Gucalp, R. Randomized Phase II trial of High Dose Interleukin 2 either alone or in combination with interferon alpha 2B in advanced renal cell carcunoma. J. Clin. Oncol., 1993, 11, 661-670.
45. Sparano, J.A.; Fisher, R.I.; Sunderland, M.; Margolin, K.; Ernest, M.L.; Sznol, M.; Atkins, M.B.; Dutcher, J.P.; Micetich, K.C.; Weiss, G.R. Randomized Phase III trial of treatment with high dose interleukin-2 either or in combination with alpha-2A in patients with advanced melanoma. J. Clin. Oncol., 1993, 11, 1969-1977.
46. Figlin, R.A.; Thompson, J.A.; Bukowski, R.M.; Vogelzang, N.J.; Novick, A.C.; Lange, P.; Steinberg, G.D.; Belldegrun, A.S. Multicenter, randomized, phase III trials CD8+ tumor infiltrating lymphocytes in combination with recombinant interleukin 2 in metastatic renal cell carcinoma. J. Clin. Oncol., 1999, 17, 2521.
47. Benlalam, H.; Labarriere, N.; Linard, B., Derre, L., Diez, E.; Pandolfino, M.C.; Bonneville, M.; Jotereau, F. Comprehensive analysis of the frequency of recognition of melanoma-associated antigen (MAA) by CD8+ melanoma infiltrating lymphocytes (TILs): Implications for Immunotherapy. Eur. J. Immunol., 2001, 31, 2007-2015.
48. Topalian, S.L.; Rivoltini, L.; Mancini, M.; Markus, N.R.; Robbins, P.F.; Kawakami, Y.; Rosenberg, S.A. Human CD4+ T cells specifically recognise a shared melanoma-associated antigen encoded by the tyrosinase gene. Proc. Natl. Acad. Sci. U.S.A., 1994, 91, 9461-9465.
49. Bakker, A.B.; Schreurs, M.W.; de Boer, A.J.; Kawakami, Y.; Rosenberg, S.A.; Adema, G.J.; Figdor, C.G. Melanocyte lineage specific antigen Gp100 is recognized by melanoma derived tumor infiltrating lymphocytes. J. Exp. Med., 1994, 179, 1005-1009.
50. Sosman, J.A.; Carillo, C.; Urba, W.J.; Flaherty, L.; Atkins, M.B.; Clark, J.I.; Dutcher, J.; Margolin, K.A.; Mier, J.; Gollob, J.; Kirkwood, J.M.; Panka, D.J.; Crosby, N.A.; O'Boyle, K.; LaFleur, B.; Ernstoff, M.S. Three Phase II cytokine working group trials of gp100(210M) peptide plus High-Dose Interleukin-2 in patients with HLA-A2-positive Advanced Melanoma. J. Clin. Oncol., 2008, 26, 2292-2298.
51. Schwartzentruber, D.J.; Lawson, D.; Richards, J.; Conry, R.M.; Miller, D.; Triesman, J.; Gailani, F.; Riley, L.B.; Vena, D.; Hwu, P. A Phase III multi-institutional randomized study of immunization with the gp100:209-217(210M) peptide followed by high dose IL-2 compared with high dose IL-2 alone in patients with metastatic melanoma. J. Clin. Oncol., 2009, 27, 18s(suppl).
52. Smith, F.O.; Downey, S.G.; Klapper, J.A.; Yang, J.C.; Sherry, R.M.; Royal, R.E., Kammula, U.S.; Hughes, M.S.; Restifo, N.P.; Levy, C.L.; White, D.E.; Steinberg, S.M.; Rosenberg, S.A. Treatment of metastatic melanoma using Interleukin-2 alone or in conjunction with vaccines. Clin. Can. Res., 2008, 14, 5610-5618.
53. Kaufman, H.L.; Taback, B.; Sherman, W.; Kim, D.W.; Shingler, W.H.; Moroziewicz, D.; DeRaffele, G.; Mitcham, J.; Carroll, M.W.; Harrop, R.; Naylor, S.; Kim-Sculze, S. Phase II trial of Modified Vaccinia Ankara(MVA) virus expressing 5T4 and high dose Interleukin-2 in patients with metastatic renal cell carcinoma. J. Trans. Med., 2009, 7, 2.
54. Brown, D.M.; Kamperschroer, C.; Dilzer, A.M.; Roberts, D.M.; Swain, S.L. IL-2 and antigen dose differentially regulate perforinand FasL-mediated cytolytic activity in antigen specific CD4+ T cells. Cell Immunol., 2009, 257, 69-79.
55. Van Herpen, C.M.L.; Jansen, R.L.H.; Kruit, W.H.J.; Hoekman, K.; Groenewegen, G.; Osanto, S.; DeMulder, P.H. Immunochemotherapy with Interleukin-2, Interferon-alpha and 5-fluorouracil for progressive metastatic renal cell carcinoma - a multicenter phase II study. Br. J. Cancer, 2000, 82, 772-776.
56. Hong, S.; Kwak, C.; Lee, S. Adjuvant interleukin 2, interferon alpha and 5-fluorouracil immunochemotherapy after radical nephrectomy for locally advanced renal cell carcinoma. Urology, 2005, 66, 518-522.
57. Legha, S.S.; Ring, S.; Eton, O.; Bedikian, A.; Buzaid, A.C.; Plager, C.; Papadopoulos, N. Development of a biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, dacarbazine, interferon alpha and Interleukin-2 for patients with metastatic melanoma. J. Clin. Oncol., 1998, 16, 1752-1759.
58. Atkins, M.B.; Hsu, J.; Lee, S.; Cohen, G.I.; Flaherty, L.E.; Sosman, J.A.; Sondak, V.K.; Kirkwood, J.M.; Eastern Cooperative Oncology Group. Phase III trial comparing concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b with cisplatin, vinblastine, and dacarbazine alone in patients with metastatic malignant melanoma (E3695): a trial coordinated by the Eastern Cooperative Oncology Group. J. Clin. Oncol., 2008, 26, 5748-5754.
59. Tarhini, A.A.; Kirkwood, J.M.; Gooding, W.E.; Cai, C.; Agarwala, S.S. Durable complete responses with high dose bolus Interleukin-2 in patients with metastatic melanoma who have experienced progression after biochemotherapy. J. Clin. Oncol., 2007, 25, 3802-3807.
60. Tarhini, A.A.; Kirkwood, J.M.; Gooding, W.E.; Moschos, S.; Agarwala, S.S. A Phase 2 trial of sequential temozolomide therapy followed by High-Dose Interleukin-2 therapy for Metastatic Melanoma. Cancer, 2008, 113, 1632-1640.
61. Gunturu, K.S.; Meehan, K.R.; Mackenzie, T.A.; Crocenzie, T.S.; McDermott, D.; Usherwood, E.J.; Margolin, K.A.; Crosby, N.A.; Atkins, M.B.; Turk, M.J.; Ahonen, C.; Fuse, S.; Clark, J.I.; Fisher, J.L.; Noelle, R.J.; Ernstoff, M.S. Cytokine working group study of lympho-depleting chemotherapy, Interleukin-2 and Granulocyte-Monocyte colony stimulating factoring patients with metastatic melanoma: Clinical outcomes and peripheral blood cell recovery. J. Clin. Oncol., 2010, 28, 1196-1202.
62. Garcia, J.A.; Rini, B.I.; Mekhail, T.; Triozzi, P.; Elson, P.; Nemec, C.; Bukowski, R.M. A phase II trial of low dose IL-2 and bevacizumab in patients with metastatic renal cell carcinoma. J. Clin. Oncol., 2007, 25, 5103.
63. Huland, E.; Hienzer, H.; Huland, H.; Yung, R. Overview of inhalational IL-2 therapy. Cancer J. Sci. Am., 2000, 6, S104-112.